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Medici
BergenAbstract—Point shear wave elastography (pSWE) is an ultrasound-based method for non-invasive quantification
of liver fibrosis. The objective of this study was to explore liver pSWE in patients with primary sclerosing cholan-
gitis (PSC) for assessment of fibrosis. Fifty-five non-transplant patients with PSC (38 males, 17 females; mean age:
46.4 y) were included and compared with 24 matched controls. Median (range) PSC duration was 8.1 (0–33) y. Ul-
trasonographic scanning followed by liver stiffness measurement by pSWE was performed using a conventional
ultrasound system (Philips iU22). Signs of liver fibrosis on B-mode were identified in 21 patients (38%). Spleno-
megaly was found in 19 patients (35%) and ascites in two patients (4%). Successful pSWE measurements were
achieved in the right liver lobe of all individuals and in the left liver lobe of 36 patients (65.5%). PSC patients
had significantly higher median shear wave velocity (SWV) than controls in the right liver (median [range]
SWV 1.26 [0.73–2.57] m/s vs. 1.09 [0.88–1.25] m/s, p , 0.001). SWV measured in the left liver lobe and spleen
did not differ between PSC patients and controls. Our findings indicate that PSC patients have increased median
SWV, indicatingmore fibrosis comparedwith controls; however, a wide range of SWVvalues were obtained among
PSC patients, possibly reflecting the various stages in disease development. (E-mail: mette.vesterhus@
helse-bergen.no)  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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raphy, Ultrasound.INTRODUCTION
Primary sclerosing cholangitis (PSC), a chronic inflam-
matory disease affecting the biliary tree, leads to liver
fibrosis and cirrhosis over time, with a reported median
transplant-free survival time of 12–21 y (Boonstra et al.
2013; Broome et al. 1996). Medical therapy with
proven benefit is lacking, and PSC is a frequent
indication for transplantation.
A major challenge in PSC is the lack of valid prog-
nostic markers and biomarkers of disease activity
(Hirschfield et al. 2013; Karlsen et al. 2014).
Fibrogenesis is an important pathogenetic pathway in
PSC and a target of treatment in several clinical trials.ddress correspondence to: Mette Vesterhus, Department of
ne, Haukeland University Hospital, Jonas Lies vei 49, N-5021
, Norway. E-mail: mette.vesterhus@helse-bergen.no
2146A serum marker panel of fibrosis, the enhanced liver
fibrosis (ELF) test, was reported to distinguish mild
from advanced disease in PSC by an area under the
curve of 0.81 and to predict prognosis independently of
other biomarkers, underscoring the importance of
accurate liver fibrosis estimation in PSC (Vesterhus
et al. 2015). However, for other etiologies of liver fibrosis,
some studies indicate an improved performance of ultra-
sound elastography compared with ELF or an incremen-
tal value of the combination of the ELF test and liver
stiffness evaluation by ultrasound elastography
(Cobbold et al. 2010; Wahl et al. 2012). Hence, better
methods for the diagnosis, grading and monitoring of
liver fibrosis are warranted.
Ultrasound elastography is a technique measuring
liver stiffness as an expression of fibrosis and has
emerged as an important tool in the diagnosis and
follow-up of liver fibrosis and cirrhosis, largely replacing
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Ferraioli et al. 2015). The status of liver biopsy as the
gold standard for liver fibrosis assessment has long
been challenged because of its invasiveness and risk of
serious complications, as well as the substantial
sampling error and inter-observer variation between pa-
thologists (Castera and Pinzani 2010; Cholongitas et al.
2006; Thampanitchawong and Piratvisuth 1999). Liver
biopsy is generally not indicated in PSC for either
diagnosis or follow-up because of the patchy disease dis-
tribution and consequent sampling bias, except in cases of
suspected small-duct disease or autoimmune hepatitis
overlap (Chapman et al. 2010; European Association
for the Study of the Liver 2009). Ultrasound
elastography has the advantages of being non-invasive
and repeatable and offers the possibility of investigating
several regions of the liver, thus reducing sampling
bias. Guidelines for the use of elastography in clinical
practice have been published (Bamber et al. 2013;
Cosgrove et al. 2013); however, reports on elastography
in PSC are scarce (Corpechot et al. 2006; Hagstrom
et al. 2012; Righi et al. 2012).
Interestingly, a recent publication reported that base-
line values of transient elastography (TE), as well as the
change in liver stiffness measured by TE, are associated
with clinical outcome in PSC (Corpechot et al. 2014).
Point shear wave elastography (pSWE) is a more recent
technology than TE, with the advantage of being incorpo-
rated into high-end ultrasound equipment, allowing B-
mode ultrasound guidance of elastography measurements
and an integration of liver stiffness measurement with a
full evaluation of the liver. Some studies of pSWE in pa-
tient populations with chronic liver disease of heteroge-
neous etiologies have included PSC patients in small
numbers insufficient for sub-analysis (Righi et al.
2012). To our knowledge, there are no studies exploring
pSWE in PSC alone. In this study, we aimed to evaluate
liver stiffness in PSC patients and compare them with
healthy controls using ultrasound pSWE.METHODS
Patient population and data collection
The protocol was in accordancewith the Declaration
of Helsinki and approved by the Regional Committee for
Health and Research Ethics in Western Norway. Patients
invited to participate in the study belonged to a known
cohort of non-transplanted PSC patients in western Nor-
way. Informed written consent was obtained from each
patient enrolled. PSC patients with a histologically
confirmed diagnosis of autoimmune hepatitis (AIH)
were classified as PSC–AIH overlap. Patients were exam-
ined, and patient records were searched for information
on clinical data, including ascites, encephalopathy,esophageal varices, variceal bleeding and inflammatory
bowel disease status at the time of serum extraction. On
the day of ultrasound and elastography, blood was
sampled and biochemical analyses were performed using
the standard routine laboratory protocols, including C-
reactive protein, hemoglobin, leukocytes, platelets,
creatinine, total bilirubin, albumin, International Normal-
ization Ratio, aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase and g-glutamyl
transferase. The Aspartate Aminotransferase-to-Platelet
Ratio Index (APRI) and Fibrosis-4 (FIB-4) scores of
fibrosis were calculated using published algorithms
(Sterling et al. 2006; Wai et al. 2003). Mayo risk scores
were calculated using the algorithm for the revised
Mayo risk score (Kim et al. 2000). Blood samples were
not taken from healthy controls.
B-Mode ultrasound examination
Immediately before pSWE examination, all patients
underwent B-mode ultrasound scanning of the liver and
spleen. All examinations were performed by a single
operator (M.V.) using a standardized scanning protocol
on a Philips iU22 (Philips Healthcare, Andover, MA,
USA) scanner. Scores were registered for liver capsule
regularity, parenchyma heterogeneity, liver angle appear-
ance, presence of ascites, gallbladder stones or polyps
and the presence of bile duct variability or sludge. Mea-
sures were taken for liver size in a sagittal section in
the medioclavicular line; gallbladder length, width and
area; spleen length and width; and portal vein diameter.
Splenomegaly was defined as spleen length .12 cm.
Point shear wave elastography
Liver and spleen stiffness was measured in the fast-
ing condition by pSWE using a conventional ultrasound
system (ElastPQ, iU22, Philips Healthcare) equipped
with a convex probe (C5-1). For liver measurements, pa-
tients and controls were examined in the supine position
with their right arm maximally abducted. A 0.5 3 1.5-
mm region of interest was placed 2–6 cm deeper than
the liver capsule in hepatic tissue, avoiding large vessels
or bile ducts (Fig. 1). Right lobe measurements were
made in an intercostal position, whereas left liver lobe
measurements were performed in a subcostal epigastric
position, with sampling from the central portion of the
left liver lobe. Spleen stiffness was measured by pSWE
from a left-side intercostal position. All pSWE measure-
ments were acquired in relaxed mid-breath hold with
minimal scanhead pressure being applied. A valid mea-
surement was defined as the median value of 10 acquisi-
tions, provided the requirement for a success rate $60%
was also fulfilled. The acquisitions were performed dur-
ing separate breath holds in the same general area within
one segment, avoiding visible bile ducts and blood
Fig. 1. Screen image of Philips iU22 in Elasto mode. B-Mode
ultrasound image of a section of the right liver lobe in a patient
with percutaneous sclerosing cholangitis. The rectangular box
represents the region of interest where the elastography mea-
surements are being performed. The region of interest has a
fixed size but can be moved freely within the image down to a
maximum depth of 8 cm. Measurements within 1 cm of the liver
capsule or close to large vessels or bile ducts should be avoided.
The measured SWV is given in the lower left corner; in this case
it is 1.55 m/s, which indicates some degree of fibrosis.
SWV 5 shear wave velocity.
Table 1. Baseline characteristics of 55 patients with PSC
and 20 healthy controls undergoing ultrasound
elastography
Baseline characteristics PSC patients Controls p
N 55 24
Males 37 (67%)* 11 (46%) 0.07
Age, mean (95% CI) 46 (42, 51) 43 (37, 49) 0.35
Age at diagnosis 34 (12–73) NA
Body mass index,
mean (95% CI)
25.8 (24.8–26.8) 24.3 (22.9–25.8)y 0.09
PSC duration, y 8.1 (20.6 to 32.8) NA
2148 Ultrasound in Medicine and Biology Volume 42, Number 9, 2016vessels. Results were given as median shear wave veloc-
ity (SWV) in meters per second. All measurements were
performed by a single investigator (M.V.). To evaluate the
intra- and inter-observer variation, pSWE of the right
liver lobe was performed twice in 16 healthy controls
by the same investigator (M.V.) or two independent inves-
tigators (M.V. and A.M.), respectively, according to the
protocol described previously.Inflammatory bowel
disease, ever
47 (85.5%) 0
Ulcerative colitis 32 (58.2%) 0
Crohn’s disease 8 (14.5%) 0
Indeterminate
colitis
7 (12.7%) 0
Cholecystectomy 4 (7.3%) 0
Mayo risk score 20.4 (22.1 to 1.9) NA
Laboratory data
ALP, U/L 138 (25–838) NI
AST, U/L 45 (20–129) NI
ALT, U/L 49 (19–390) NI
Total bilirubin,
mmol/L
11 (5–75) NI
g-Glutamyl
transpeptidase,
U/L
177 (17–1576) NI
Albumin, g/L 46 (36–53) NI
INR 1.0 (0.9–1.2) NI
Platelets, 109/L 227 (60–765) NIStatistical analyses
Version 12.7.0.0 of SPSS 22 (IBM, Armonk, NY,
USA) and MedCalc were used to perform all statistical
analyses, and p values, 0.05 were considered to indicate
significance. Variables were tested for normal distribu-
tion, and Student’s t-test or the Mann–Whitney U-test
were applied as appropriate. Data are presented as
mean (SD), or as median (range) when the data were
not normally distributed. Correlations between SWV
and clinical parameters, biochemical scores of fibrosis
or Mayo risk scores were tested by Spearman’s rank order
correlation coefficient (r). Intra-observer agreement was
tested using the limits of agreement method (Bland and
Altman 1999).ALP 5 alkaline phosphatase; ALT 5 alanine aminotransferase;
AST 5 aspartate aminotransferase; CI, confidence interval; INR 5 In-
ternational Normalization Ratio; NA5 not applicable; NI 5 not inves-
tigated; PSC 5 primary sclerosing cholangitis.
* Values are expressed as n (%) or median (range) unless otherwise
noted.
y N 5 17.RESULTS
Sixty-four non-transplant PSC patients in a region of
western Norway were identified and invited to partici-
pate; 55 (86%, 38 males, 17 females; mean age: 46.4 y;95% confidence interval [CI]: 42.0–50.8) were included
and compared with 24 healthy controls matched for age
and gender. Median (range) PSC duration was 8.1 (0–
33) y. Baseline demographic characteristics and clinical
and laboratory data are summarized in Table 1. One pa-
tient with small-duct PSC and 5 patients with PSC–AIH
overlap syndrome were included. In total, 3 patients
had biochemical signs of clinically significant cholestasis
or hepatitis as determined by a bilirubin level.30 (2 pa-
tients) or an alanine aminotransferase or aspartate amino-
transferase level .53 the upper limit of normal (1
patient). There were no significant differences in distribu-
tion of age, gender or body mass index (BMI) between
patients and controls. On the basis of B-mode ultrasound
evaluation, signs compatible with advanced liver fibrosis,
including liver capsule irregularity, periductal fibrosis
and coarse liver parenchyma, were identified in 16
(29%), 5 (9%) and 12 (22%) patients, respectively,
whereas 34 (62%) patients displayed no signs of fibrosis
on B-mode ultrasound. Splenomegaly was found in 19
patients (35%) and ascites in 2 (4%) patients. Bile duct
Liver pSWE in primary sclerosing cholangitis d A. B. MJELLE et al. 2149dilation was identified in 25 (46 %) patients. B-Mode ul-
trasound findings are summarized in Table 2.
pSWE of the right liver lobe
The intra- and inter-observer agreement for pSWE
of the right liver lobe in the healthy controls was good,
as evaluated by the limits of agreement method (Fig. 2).
In PSC patients, valid pSWE measurements were
achieved in all patients for the right liver lobe. The me-
dian success rate for the individual patients was 100%
(range: 71.4%–100%). PSC patients had higher median
SWV compared with the healthy controls (1.26 [0.73–
2.57] and 1.09 [0.88–1.25] m/s, respectively,
p , 0.001) (Fig. 3a). Area under the receiver operating
characteristic curve (AUROC) analysis revealed fairly
good discrimination for median SWV of the right liver
lobe between PSC patients and controls, with an AUROC
of 0.775 (95%CI: 0.67–0.86) (Fig. 4). For the discrimina-
tion of PSC patients from controls, the statistically
optimal cutoff for SWV as decided by Youden’s index
was 1.24 m/s, with a sensitivity and specificity of 56.4
and 95.8, respectively.
Figure 5 illustrates right liver SWVs correlated with
APRI and FIB-4 scores (r 5 0.494, p 5 0.001, and
r 5 0.368, p 5 0.017, respectively) (Fig. 5a and b),
whereas there was no significant correlation with the
Mayo risk score (r5 0.296, p5 0.06) (Fig. 5c). No corre-
lation was found between right liver SWVs and BMI, age
or PSC duration (Table 3).
SWV in the right liver lobe was significantly higher
in PSC patients with coarse liver parenchyma (median
[range]: 1.88 [0.99–2.57] m/s vs. 1.22 [0.73–2.34] m/s,
p 5 0.002), irregular liver capsule (1.81 [1.11–2.57] m/Table 2. B-Mode ultrasound findings in PSC patients
Liver
Liver size in MCL, cm 14.2 (8.0–28.5)*
Hepatomegaly (.16 cm) 10 (18.2%)
Liver capsule irregularity 16 (29.1%)
Coarse liver parenchyma 12 (21.8%)
Blunted liver angle 16 (29.1%)
Ascites 2 (3.6%)
Gallbladder and bile ducts
Gallbladder length, cm 6.6 (2.1–10.0)
Gallbladder width, cm 3.0 (1.5–5.4)
Gallbladder wall thickness, mm 2.3 (0.3–10.4)
Gallbladder stone(s) 6 (10.9%)
Gallbladder polyp 1 (1.8%)
Cholecystectomy 4 (7.3%)
Bile duct variability 25 (45.5%)
Periductal fibrosis 5 (9.1%)
Spleen
Spleen length, cm 12.6 (8.2–22.7)
Spleen area, cm2 58.3 (25.4–165.7)
Splenomegaly (.13 cm) 19 (34.5%)
MCL 5 medioclavicular line; PSC 5 percutaneous sclerosing
cholangitis.
* Values are expressed as n (%) or median (range).
Fig. 2. Intra- and inter-observer agreement of point shear wave
elastography of the right liver lobe in healthy controls. The
Bland–Altman plots illustrate the (a) intra-observer and (b)
inter-observer differences in liver stiffness evaluation measured
by point shear wave elastography using ElastPQ (iU22, Philips)
and expressed as shear wave velocity in meters per second. The
horizontal solid lines represent the intra- or inter-observer
mean 6 2 SD (limits of agreement, dashed horizontal lines),
respectively. A valid measurement was defined as the median
of 10 valid acquisitions with a success rate.60%. Themeasure-
ments were performed twice by one (a) or two (b) observer(s) on
the same day in the right liver lobe of healthy controls for the
intra-observer agreement assessment.s vs. 1.17 [0.73–2.43] m/s, p 5 0.001) and periductal
fibrosis (1.76 [1.27–2.09] m/s vs. 1.24 [0.73–2.57] m/s,
p5 0.049), compared with patients with normal findings
(Fig. 6a–c). Patients with none of these three visual signs
of liver fibrosis had a median right liver SWV of 1.17
(0.73–2.34) m/s, compared with 1.76 (0.99–2.57) m/s
among patients with minimum one B-mode sign of
fibrosis (p 5 0.001) (Fig. 6c). Right liver stiffness
Fig. 3. Liver stiffness in PSC patients compared with controls.
Liver stiffness evaluation by point shear wave elastography us-
ing iU22 (Philips) in 55 PSC patients and 24 healthy controls
matched for age and gender in (a) the right liver lobe, and (b)
the left liver lobe revealed increased liver stiffness in the right
liver lobe of PSC patients compared with controls
(p , 0.001). No significant difference could be found in the
left liver lobe (p 5 0.11). Liver stiffness is expressed as shear
wave velocity in meters per second. PSC 5 primary sclerosing
cholangitis.
Fig. 4. Point shear wave elastography discriminates between
primary sclerosing cholangitis patients and controls. Area under
the receiver operating characteristic curve analysis revealed
fairly good discrimination for median SWV measured by point
shear wave elastography between 55 primary sclerosing cholan-
gitis patients and 24 age- and gender-matched controls with an
area under the curve of 0.775 (95% confidence interval: 0.67–
0.86). The optimal cutoff for SWVas decided by Youden’s index
was 1.24 m/s, with a sensitivity and specificity of 56.4 and 95.8,
respectively. SWV 5 shear wave velocity.
2150 Ultrasound in Medicine and Biology Volume 42, Number 9, 2016assessed by median SWV did not differ significantly be-
tween patients with splenomegaly and patients without
splenomegaly (1.42 [0.73–2.57] m/s vs. 1.24 [0.93–
2.34] m/s, p 5 0.11). Bile duct dilation was identifiedin 26 (47.3%) patients, but median right liver SWV did
not differ between these patients and patients without
bile duct dilation (1.32 [0.93-2.57] m/s vs. 1.24 [0.73-
2.43] m/s, p 5 0.61).pSWE of the left liver lobe
In the left liver lobe, valid SWVmeasurements were
acquired in 36 patients (66%), whereas in 19 patients
(35%) themeasurements were considered invalid because
of too many failed acquisitions (success rate: ,60%).
The median success rate was 83% (46%–100%). Left
liver lobe SWV did not significantly differ between
PSC patients and controls (median [range] SWV: 1.46
[0.59–3.68] m/s vs. 1.13 [0.91–1.24] m/s, p 5 0.11)
(Fig. 3 b). There was no significant difference between
median SWVof the right and left liver lobes in PSC pa-
tients (p 5 0.41). Paired SWV values of the right and
left liver lobes in the individual patient did not signifi-
cantly correlate (r 5 0.233, p5 0.17). Similarly, no sig-
nificant correlation was found between left liver SWVs
and BMI, age or PSC duration (Table 3).pSWE of the spleen
Valid measurements were obtained in 37 PSC pa-
tients (67.3%), whereas in the remainder of the patients,
measurements either were not performed (n 5 16) or
Fig. 5. Associations of liver stiffness with fibrosis scores and
prognosis in percutaneous sclerosing cholangitis patients. The
scatterplots with regression lines illustrate that SWV (m/s) of
the right liver lobe as measured by point shear wave elastogra-
phy using the iU22 (Philips) was correlated with the (a) APRI
=
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cess rate for the patients with valid measurements was
100% (76.9%–100%). There was no significant difference
between PSC patients and controls (median SWV: 1.47
[0.79–3.13] m/s and 1.48 [1.17–1.80] m/s, respectively,
p 5 0.83). A tendency toward higher spleen SWV in pa-
tients with splenomegaly compared with patients without
splenomegaly did not reach statistical significance
(1.71 m/s [0.89–2.71] vs 1.39 m/s [0.79–3.13], respec-
tively, p5 0.05).There was no correlation between spleen
SWV and right or left liver SWV (1.47 m/s vs. 1.24 m/s,
N 5 37, r 5 0.104, p 5 0.54, and 1.39 m/s vs. 1.50 m/
s, N5 22, r5 0.331, p5 0.13, respectively). One patient
had variceal bleeding but did not have a high spleen SWV
(median SWV: 1.55 m/s). No correlation was found be-
tween spleen SWVand BMI, age or PSC duration.DISCUSSION
Our study indicates how liver fibrosis can be evalu-
ated by both SWE and traditional B-mode findings during
the same procedure. We found excellent intra- and inter-
observer variation for pSWE using the iU22 system for
the right liver lobe, in line with previous reports (Ling
et al. 2013). The non-invasive evaluation of the degree
of and change in liver fibrosis in PSC may be of major
importance in evaluating the stage and prognosis of the
disease, as indicated by recent reports (Corpechot et al.
2014, Vesterhus et al. 2015).
Liver biopsy is generally not indicated in PSC, based
on the inherent sampling error resulting from the patchy
distribution of fibrosis (European Association for the
Study of the Liver 2009). The flaws of biopsies were illus-
trated in a study of whole-section scanning of 50 liver ex-
plants from patients with primary biliary cirrhosis,
another disease of the biliary tree, in which only 20%
of the primary biliary cirrhosis livers had a consistent his-
tologic stage of fibrosis throughout the liver at clinically
defined end-stage disease (Garrido and Hubscher 1996).
Likewise, the distribution of liver fibrosis in PSC is un-
even and follows the bile ducts to a large extent. In our
opinion, it may therefore be preferable to use non-
invasive methods assessing liver fibrosis covering larger
areas of the liver in PSC. Ultrasound shear wave elastog-
raphy is non-invasive and repeatable, can be integrated
into a full liver examination and has been documen-
ted in viral hepatitis as a means of measuring liver
fibrosis, but has not been previously explored in PSCand (b) Fibrosis-4 (Fib4) scores of fibrosis, but not with (c)
the Mayo risk score, a commonly used prognostic score in
primary sclerosing cholangitis. SWV 5 shear wave velocity;
APRI 5 Aspartate Aminotransferase-to-Platelet Ratio Index.
Table 3. Correlations of median SWV with other
continuous variables in PSC patients
Clinical and
laboratory variables
Median SWV right liver median SWV left liver
N
Spearman’s
r p N
Spearman’s
r p
Age 55 20.004 0.974 36 20.064 0.709
Age at
diagnosis
54 20.06 0.669 36 0.115 0.504
PSC duration 54 0.01 0.945 36 20.179 0.295
Bilirubin 49 0.175 0.23 32 0.207 0.255
Albumin 50 20.358 0.011* 33 20.222 0.215
ALP 50 0.246 0.085 33 0.335 0.057
AST 42 0.208 0.187 26 0.191 0.35
ALT 51 20.072 0.616 34 0.222 0.207
Platelet count 51 20.319 0.022 34 20.301 0.084
Body mass
index
55 20.101 0.463 36 0.281 0.097
INR 47 0.325 0.026 31 20.115 0.539
Mayo score 41 0.296 0.06 25 0.495 0.012
APRI score
(AST/TRC)y
42 0.494 0.001 26 0.468 0.016
ALP 5 alkaline phosphatase; ALT 5 alanine aminotransferase;
AST 5 aspartate aminotransferase; APRI 5 AST-to-Platelet Ratio In-
dex; INR 5 International Normalization Ratio; NA 5 not applicable;
PSC 5 primary sclerosing cholangitis; SWV 5 shear wave velocity.
* p-Values in italic denote significance.
y See Figure 5a.
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Sporea et al. 2012a, 2012b).
Our findings suggest that PSC patients have
increased median liver stiffness as expressed by SWV
compared with healthy controls. The literature reveals
scarce information about pSWE in PSC, but our data
are in line with pSWE findings in a pilot study of patients
with autoimmune liver diseases causing fibrosis,
including PSC (Righi et al. 2012), and support previous
findings describing TE in PSC (Corpechot et al. 2006,
2014; Hagstrom et al. 2012). In the present PSC cohort,
21 (38%) of the patients expressed B-mode signs of
liver fibrosis. SWV was significantly higher in patients
with B-mode signs of liver fibrosis; however, 12
patients without visual signs of liver fibrosis also had
increased SWV (.1.24 m/s). Previous studies have
reported good to excellent AUROCs between pSWE
and histologic evaluation of fibrosis, even in
autoimmune liver diseases (Friedrich-Rust et al. 2012;
Righi et al. 2012). Thus, our findings could suggest an
increased sensitivity in identifying fibrosis in PSC
patients by adding elastography to an ultrasound liver
evaluation. Furthermore, pSWE was associated with
currently acknowledged signs of fibrosis, including TE
in cystic fibrosis liver disease, which displays a patchy
disease distribution similar to that of PSC (Behrens
et al. 2013; Karlas et al. 2012; Manco et al. 2012;
Monti et al. 2012). Because liver biopsy is generally
not indicated in PSC, histologic correlates are lackingin the present study, but SWV correlated with serum-
based scores of fibrosis, including APRI and FIB-4
scores.
Previous studies have reported that the performance
of SWE and the cutoff values for significant fibrosis and
cirrhosis may vary with the etiology of liver disease
(Friedrich-Rust et al. 2012; Guzman-Aroca et al. 2012;
Karlas et al. 2012; Sporea et al. 2012b). In the present
study, the cutoff SWV value with the best statistical
power to discriminate between PSC patients and
healthy controls was 1.24 m/s with an area under the
curve of 0.775, in line with previous findings
suggesting 1.23 m/s as the statistically best cutoff
between patients with chronic liver disease and controls
(Sporea et al. 2014). It is an interesting characteristic of
patients with PSC that this cutoff is similar to that of other
liver disease populations, although it should be kept in
mind that the clinically ideal cutoff value may differ de-
pending on the aim of stratification (e.g., early diagnosis
of liver fibrosis or identification of a high-risk group).
Longitudinal studies are needed to resolve whether
pSWE can be used to follow disease progression in the in-
dividual patient for prognostic purposes.
The wider variability and lower success rate of ultra-
sound elastography of the left liver lobe has been debated
(Karlas et al. 2011; Ling et al. 2013; Toshima et al. 2011).
We were able to obtain valid liver stiffness measurements
of the left liver lobe in 66% of the patients. SWVs of the
left liver lobe correlated with the APRI score of fibrosis.
There was a wider range of SWV measurements in the
left compared with the right liver, probably caused by
respiratory and cardiac movements affecting
elastography measurements and suggesting reduced
reliability of measurements in the left liver lobe. The
lack of correlation between the two liver lobes may be
due to the higher variability in SWV of the left liver
lobe, and the definition of stricter quality criteria for
pSWE measurements of the left liver lobe might yield
better correlation for the valid measurements.
Previously published studies have indicated that
cholestasis influences the accuracy of pSWE for the
non-invasive evaluation of liver fibrosis (Pfeifer et al.
2014). PSC is a cholestatic disease, and this might be ex-
pected to complicate the evaluation of liver stiffness by
pSWE in this patient group. However, only two patients
had significantly elevated bilirubin .30 mmol/L; and
although some degree of cholestasis was indicated in 26
(47%) patients by bile duct dilation on B-mode ultra-
sound, there was no difference in liver stiffness by
pSWE in these patients compared with patients without
bile duct dilation.
Several articles have reported that increased spleen
stiffness alone or the spleen/liver stiffness ratio may pre-
dict high-risk esophageal varices and, thus, aid the
Fig. 6. Point shear wave elastography and B-mode signs of liver
fibrosis. Boxplots illustrate SWV (m/s) reflecting liver stiffness
as evaluated by point shear wave elastography using the iU22
=
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dergo gastroscopy (Berzigotti et al. 2013, 2014; Takuma
et al. 2013; Sirli et al. 2015). In view of this, the spleen
stiffness of PSC patients is of interest. In the present
study, spleen stiffness did not significantly differ
between PSC patients and controls. However, the
number of patients was small, and only one variceal
bleeding was observed in this cohort, precluding
definitive conclusions. The association of liver and
spleen stiffness with portal hypertension and esophageal
varices in PSC should be further investigated in a larger
cohort and, preferably, in a prospective setting.Limitations of the study
The lack of liver biopsies in our cohort represents a
limitation to the study. However, liver biopsies are not
indicated in PSC, and biopsy was considered unethical
for study purposes. Previous studies of chronic liver dis-
ease with a range of etiologies have repeatedly indicated
excellent correlation between pSWE and histology find-
ings. The question of prognostic value cannot be
answered by the cross-sectional design of the present
study, and further studies, including prospective follow-
up, are warranted.
Although no standards of quality control have been
agreed on for pSWE, we applied a standardized protocol
and strict quality criteria as previously proposed,
demanding 10 valid acquisitions with a success rate
.60% to have reliable results (Bota et al. 2013a,
2013b). Measurements were made in two selected sites
in the right and left liver lobes, respectively.
Considering the patchy disease distribution in PSC, it is
conceivable that SWV measurements throughout the
entire liver would have revealed variable results within
each lobe of the individual patient, and further studies
should attempt to explore this.CONCLUSIONS
We found that PSC patients have increased SWV in
their liver parenchymacomparedwithhealthycontrols, indi-
cating increased liver fibrosis. However, a wide range of
SWV values were obtained for PSC patients, possibly re-
flecting various stages in PSC disease development. This
novel method exhibited low intra- and inter-observer varia-
tion,making it suitable for further studies analyzingprospec-
tive follow-up data evaluating pSWE as a prognostic tool.(Philips) in patients with and without B-mode ultrasound signs
of fibrosis, including (a) coarse liver parenchyma, (b) irregular
liver capsule and (c) any of three signs of liver fibrosis (liver
capsule irregularity, parenchyma coarseness, periductal
fibrosis), compared with none of these.
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